The history and future of targeting cyclin-dependent kinases in cancer therapy
Open accessThe DOI matches its Crossref record; 210 of the 210 references it cites were found in a registry or an index.
Abstract
Cancer represents a pathological manifestation of uncontrolled cell division; therefore, it has long been anticipated that our understanding of the basic principles of cell cycle control would result in effective cancer therapies. In particular, cyclin-dependent kinases (CDKs) that promote transition through the cell cycle were expected to be key therapeutic targets because many tumorigenic events ultimately drive proliferation by impinging on CDK4 or CDK6 complexes in the G1 phase of the cell cycle. Moreover, perturbations in chromosomal stability and aspects of S phase and G2/M control mediated by CDK2 and CDK1 are pivotal tumorigenic events. Translating this knowledge into successful clinical development of CDK inhibitors has historically been challenging, and numerous CDK inhibitors have demonstrated disappointing results in clinical trials. Here, we review the biology of CDKs, the rationale for therapeutically targeting discrete kinase complexes and historical clinical results of CDK inhibitors. We also discuss how CDK inhibitors with high selectivity (particularly for both CDK4 and CDK6), in combination with patient stratification, have resulted in more substantial clinical activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Grade 3–4 neutropenia is observed in approximately 60% of patients taking palbociclib and ribociclib (Asghar et al., 2015; Hortobagyi et al., 2016).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Asghar et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Like palbociclib, these orally-bioavailable and highly selective CDK4/6-targeting agents exhibit IC50 values in the low nanomolar range, whereas other CDK family members are far less sensitive (1, 88, 89).”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Such pan-CDK inhibitors had limited success, due in part to the dose limiting toxicities that hampered their use (Asghar et al., 2015).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Asghar et al., 2015
The cited source says what the claim attributes to it.
In the citing paper
“More than two decades after discovery of CDK4 and CDK6, drugs inhibiting their activities are now demonstrating significant efficacy in cancer treatment [for other recent reviews, see (1-3)].”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [1]
In the citing paper
“Abemaciclib appears to be better tolerated overall, with only 55% of patients experiencing significant adverse events (as compared to 70–80% with ribociclib and palbociclib) and only 21% with grade 3–4 neutropenia.”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Asghar et al., 2015
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,890
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
BRAFE600-associated senescence-like cell cycle arrest of human naevi
Michaloglou, C., Vredeveld, L. C. W., Soengas, M. S., Denoyelle, C., Kuilman, T., van der Horst, C. M. A. M., Majoor, D. M., Shay, J. W., Mooi, W. J., & Peeper, D. S. (2005) · Nature · doi:10.1038/nature03890 · Cited by 2,160
Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization
Diehl, J. A., Cheng, M., Roussel, M. F., & Sherr, C. J. (1998) · Genes & Development · doi:10.1101/gad.12.22.3499 · Cited by 2,130
Polyak, K., Lee, M.-H., Erdjument-Bromage, H., Koff, A., Roberts, J. M., Tempst, P., & Massagué, J. (1994) · Cell · doi:10.1016/0092-8674(94)90572-x · Cited by 2,118
Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints
Bartkova, J., Rezaei, N., Liontos, M., Karakaidos, P., Kletsas, D., Issaeva, N., Vassiliou, L.-V. F., Kolettas, E., Niforou, K., Zoumpourlis, V. C., et al. (2006) · Nature · doi:10.1038/nature05268 · Cited by 1,986
Cited by
Items 301–400 of 1,002
Knudsen, E. S., Kumarasamy, V. M., Ruiz, A., Sivinski, J., Chung, S., Grant, A. D., Vail, P. J., Chauhan, S. S., Jie, T., Riall, T. S., et al. (2019) · Oncogene · doi:10.1038/s41388-018-0650-0 · Cited by 68
“Loss of CDKN2A is commonly observed in PDAC, but also occurs in colorectal, non-small-cell lung carcinoma, and melanoma that exhibit oncogenic RAS mutation [9, 10].”
Self-citationTriazole-fused pyrimidines in target-based anticancer drug discovery
Dai, X., Xue, L.-P., Ji, S., Zhou, Y., Gao, Y., Zheng, Y., Liu, H., & Liu, H. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115101 · Cited by 66
miR-1299 suppresses cell proliferation of hepatocellular carcinoma (HCC) by targeting CDK6
Zhu, H., Wang, G., Zhou, X., Song, X., Gao, H., Ma, C., Chang, H., Li, H., Liu, F., Lu, J., et al. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.07.037 · Cited by 66
“CDK6 also is a well-known target for cancer therapy, many drugs targeting for CDK6 have been synthesized, such as PD-0332991, LY-2835219 and LEE011 [13].”
BackgroundBeale, G., Haagensen, E. J., Thomas, H. D., Wang, L.-Z., Revill, C., Payne, S. L., Golding, B. T., Hardcastle, I. R., Newell, D. R., Griffin, R. J., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.238 · Cited by 67
“Preliminary clinical data with CDK inhibitors suggests they are generally well tolerated but rarely induce marked anti-proliferative toxicity or tumour regressions when given as single agents (Shapiro, 2006; Asghar et al, 2015).”
BackgroundOak, C. Z., Khalifa, A., Isali, I., Bhaskaran, N., Walker, E., & Shukla, S. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4407 · Cited by 66
“The phosphorylation of specific kinase regulates Cdks and cyclin proteins (1).”
Thangaraj, K., Balasubramanian, B., Park, S., Natesan, K., Liu, W., & Vaiyapuri, M. (2019) · Biomolecules · doi:10.3390/biom9090418 · Cited by 66
“Phosphorylation of Rb by CDK4 initiates an intricate process of phosphorylation-mediated disruption of tumor suppressor function that releases E2F and instigates subsequent G1 to S phase progression [29].”
BackgroundWaddell, A. R., Mahmud, I., Ding, H., Huo, Z., & Liao, D. (2021) · Cancers · doi:10.3390/cancers13112799 · Cited by 66
“A number of CDK4/6 kinase inhibitors such as PD 0332991 [17] (Palbociclib), LY-2835219 (Abemaciclib), and LEE011 (Ribociclib) [18] in combination with an aromatase inhibitor have been approved by the FDA for treating patients with hormone receptor-positive and HER2-negative BC.”
BackgroundMita, M. M., Mita, A. C., Moseley, J. L., Poon, J., Small, K. A., Jou, Y., Kirschmeier, P. T., Zhang, D., Zhu, Y., Statkevich, P., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.288 · Cited by 65
“CDK5 has been primarily associated with neuronal function (Kawauchi, 2014), but has also been shown to regulate RAS-RAL signalling (Feldmann et al, 2010).”
BackgroundInfluentialHassan, G. S., Georgey, H. H., Mohammed, E. Z., George, R. F., Mahmoud, W. R., & Omar, F. A. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113389 · Cited by 65
Jiang, B., Jiang, J., Kaltheuner, I. H., Iniguez, A. B., Anand, K., Ferguson, F. M., Ficarro, S. B., Seong, B. K. A., Greifenberg, A. K., Dust, S., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113481 · Cited by 64
Wu, C., Peng, S., Pilie, P. G., Geng, C., Park, S., Manyam, G. C., Lu, Y., Yang, G., Tang, Z., Kondraganti, S., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0848 · Cited by 64
“E2F proteins control the expression of a multitude of positive-acting factors that are critical for progression through the S phase and the G2–M transition (19).”
BackgroundReviewing cancer’s biology: an eclectic approach
DIORI, I. K., & Şanlıer, Ş. H. (2021) · Journal of the Egyptian National Cancer Institute · doi:10.1186/s43046-021-00088-y · Cited by 64
Enzyme-Triggered DNA Sensor Technology for Spatially-Controlled, Cell-Selective Molecular Imaging
Li, M., & Li, L. (2023) · Accounts of Chemical Research · doi:10.1021/acs.accounts.3c00085 · Cited by 64
Endometrial Carcinoma: Specific Targeted Pathways
Eritja, N., Yeramian, A., Chen, B., Llobet‐Navàs, D., Ortega, E., Colás, E., Abal, M., Dolcet, X., Reventós, J., & Matías‐Guiu, X. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-43139-0_6 · Cited by 64
CDK1 dependent phosphorylation of hTERT contributes to cancer progression
Yasukawa, M., Ando, Y., Yamashita, T., Matsuda, Y., Shoji, S., Morioka, M. S., Kawaji, H., Shiozawa, K., Machitani, M., Abe, T., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15289-7 · Cited by 64
Ocular Toxicity of Targeted Anticancer Agents
Fortes, B. H., Tailor, P. D., & Dalvin, L. A. (2021) · Drugs · doi:10.1007/s40265-021-01507-z · Cited by 64
Advances of Targeted Therapy for Hepatocellular Carcinoma
Niu, M., Yi, M., Li, N., Wu, K., & Wu, K. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.719896 · Cited by 64
“Cyclin-Dependent Kinase 4/6 (CDK4/6) CDK4/6 promotes the cell cycle progression (147, 148).”
BackgroundYadav, T., Murahari, M., Peters, G. J., & Mayur, Y. C. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114527 · Cited by 62
Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies
Steenbruggen, T. G., van Ramshorst, M. S., Kok, M., Linn, S. C., Smorenburg, C. H., & Sonke, G. S. (2017) · Drugs · doi:10.1007/s40265-017-0774-5 · Cited by 64
“proliferation and resistance to endocrine therapy [34, 72].”
Discovering and validating cancer genetic dependencies: approaches and pitfalls
Lin, A., & Sheltzer, J. M. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-020-0247-7 · Cited by 64
Wu, H., & Chu, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020636 · Cited by 64
Jayasooriya, R. G. P. T., Dilshara, M. G., Molagoda, I. M. N., Park, C., Park, S. R., Lee, S., Choi, Y. H., & Kim, G. (2018) · Oncotarget · doi:10.18632/oncotarget.24934 · Cited by 62
“After DNA damage is induced by oxidative stress, p21-induced cell cycle arrest is also activated during DNA repair, and p21 inhibits Cdk which regulates many cellular processes in a p53-depedent and independent manner [14].”
An update: emerging drugs to treat squamous cell carcinomas of the head and neck
Lee, Y. S., Johnson, D. E., & Grandis, J. R. (2018) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2018.1543400 · Cited by 62
“Dysregulation of the CDK4/6/Rb pathway is a characteristic feature of HPV (+) HNSCC.”
BackgroundInfluentialMolecular Mechanisms of Anti-Estrogen Therapy Resistance and Novel Targeted Therapies
Özyurt, R., & Özpolat, B. (2022) · Cancers · doi:10.3390/cancers14215206 · Cited by 63
“The CDK4/CDK6/cyclin D complex is negatively regulated by the INK4 and Cip/Kip protein families, which are endogenous CDK inhibitors [239].”
BackgroundCancer takes many paths through G1/S
Knudsen, E. S., Witkiewicz, A. K., & Rubin, S. M. (2023) · Trends in Cell Biology · doi:10.1016/j.tcb.2023.10.007 · Cited by 63
Self-citationKRAS mutant lung cancer: progress thus far on an elusive therapeutic target
Bhattacharya, S., Socinski, M. A., & Burns, T. F. (2015) · Clinical and Translational Medicine · doi:10.1186/s40169-015-0075-0 · Cited by 62
“The results were not published but were disappointing as there was no impact on progression free survival [41].”
BackgroundStructure‐Based Design of Selective Noncovalent CDK12 Inhibitors
Johannes, J. W., Denz, C. R., Su, N., Wu, A. J., Impastato, A. C., Mlynarski, S. N., Varnes, J. G., Prince, D. B., Cidado, J. R., Gao, N., et al. (2017) · ChemMedChem · doi:10.1002/cmdc.201700695 · Cited by 62
Shen, S., Dean, D. C., Yu, Z., & Duan, Z. (2019) · Hepatology Research · doi:10.1111/hepr.13353 · Cited by 62
Reactivation of Endogenous Retroelements in Cancer Development and Therapy
Ishak, C. A., & Carvalho, D. D. D. (2019) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033525 · Cited by 62
“CDK4/6 inhibitors were developed to inhibit G1 CDKs to promote cytostasis (Asghar et al. 2015).”
BackgroundKrämer, A., Kurz, C. G., Berger, B., Celik, I.-E., Tjaden, A., Greco, F., Knapp, S., & Hanke, T. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112770 · Cited by 62
Regulation of cancer progression by circRNA and functional proteins
Chen, J., Gu, J., Tang, M., Liao, Z., Tang, R., Zhou, L., Su, M., Jiang, J., Hu, Y., Chen, Y., et al. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30608 · Cited by 61
“It also complexes with cyclin A to promote the progression of the cell cycle in the S phase (Asghar et al., 2015; Lim & Kaldis, 2013; Marais et al., 2010). circFoxo3‐p21‐CDK2 ternary complex avoided the formation of CDK2‐cyclin E and CDK2‐cyclin A complexes, thus suppressing cell cycle progression…”
BackgroundSynthesis of pyridine derivatives for diverse biological activity profiles: A review
Allaka, T. R., & Katari, N. K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91221-1.00005-1 · Cited by 61
Guiding Mitotic Progression by Crosstalk between Post-translational Modifications
Cuijpers, S. A. G., & Vertegaal, A. C. O. (2018) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2018.02.004 · Cited by 61
Cyclin-dependent kinase inhibitors for the treatment of breast cancer: past, present, and future
DiPippo, A. J., Patel, N. K., & Barnett, C. M. (2016) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1756 · Cited by 60
“In addition, resistance to tumor growth was displayed in mice with knockouts of cyclin D1 or CDK4.(6) CDK4/6 gene amplification is noted in BC, particularly in ER-positive disease.”
BackgroundResultInfluentialAlpinetin: A Review of Its Pharmacology and Pharmacokinetics
Zhao, G., Tong, Y. A., Luan, F., Zhu, W., Zhan, C., Qin, T., An, W., & Zeng, N. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.814370 · Cited by 60
Göv, E., Kori, M., & Arğa, K. Y. (2017) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2017.0115 · Cited by 60
Wang, B., Wu, J., Wu, Y., Chen, C., Zou, F., Wang, A., Wu, H., Hu, Z., Jiang, Z., Liu, Q., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.09.025 · Cited by 60
Steroid Hormone Receptors: Links With Cell Cycle Machinery and Breast Cancer Progression
Saha, S., Dey, S., & Nath, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.620214 · Cited by 60
The evolution of cyclin dependent kinase inhibitors in the treatment of cancer
Jhaveri, K. L., Burris, H. A., Yap, T. A., Hamilton, E. P., Rugo, H. S., Goldman, J. W., Dann, S. G., Liu, F., Wong, G. Y., Krupka, H. I., et al. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1944109 · Cited by 61
“Second-generation inhibitors of multiple CDKs were subsequently explored clinically, such as dinaciclib [25–27], which inhibits CDK1, CDK2, CDK5, CDK9, CDK12, with less activity against CDK4, CDK6, and CDK7 [23,28].”
Yan, H., Ren, S., Lin, Q., Yu, Y., Chen, C., Hua, X., Jin, H., Lu, Y., Zhang, H., Xie, Q., et al. (2019) · The FASEB Journal · doi:10.1096/fj.201900499rr · Cited by 59
Ling, Y., Liu, J., Qian, J., Meng, C., Guo, J., Gao, W., Xiong, B., Ling, C., & Zhang, Y. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200102115720 · Cited by 59
EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer
Beck, T. N., Georgopoulos, R., Shagisultanova, E. I., Sarcu, D., Handorf, E. A., Dubyk, C. W., Lango, M. N., Ridge, J. A., Astsaturov, I. A., Serebriiskii, I. G., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0243 · Cited by 59
“It was noted in the same study that inhibition of CDK4/6 with abemaciclib resulted in increased activation of EGFR/HER2 signaling, similar to the response to palbociclib observed in HNSCC (Fig.”
BackgroundInfluentialCherukupalli, S., Chandrasekaran, B., Aleti, R. R., Sayyad, N., Hampannavar, G. A., Merugu, S. R., Rachamalla, H. K., Banerjee, R., & Karpoormath, R. V. (2018) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2018.08.104 · Cited by 59
Phenotypical microRNA screen reveals a noncanonical role of CDK2 in regulating neutrophil migration
Hsu, A. Y.-H., Wang, D., Liu, S., Lu, J., Syahirah, R., Bennin, D. A., Huttenlocher, A., Umulis, D. M., Wan, J., & Deng, Q. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1905221116 · Cited by 59
Lawal, B., Liu, Y., Mokgautsi, N., Khedkar, H., Sumitra, M. R., Wu, A. T. H., & Huang, H. (2021) · Biomedicines · doi:10.3390/biomedicines9010092 · Cited by 58
“Therefore, since dysfunctional cell cycle regulation via oncogenic aberrations of CDKs is a hallmark of all human cancers [15], pharmacological targeting of CDKs will undoubtedly affect cancer proliferation and survival [16,17].”
BackgroundOuh, Y., Kim, H. Y., Yi, K. W., Lee, N. W., Kim, H., & Min, K. (2024) · Diagnostics · doi:10.3390/diagnostics14040451 · Cited by 58
“In healthy cells, p16 regulates the cell cycle by inhibiting the activity of cyclin-dependent kinases 4 and 6 (CDK4/6) [37,38].”
BackgroundAdvances of small molecule targeting of kinases
Berndt, N., Karim, R. M., & Schönbrunn, E. (2017) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2017.06.015 · Cited by 59
Kassem, L. M. H., Shohdy, K. S., Lasheen, S., Abdel-Rahman, O. M., & Bachelot, T. (2017) · Breast Cancer · doi:10.1007/s12282-017-0818-4 · Cited by 58
Saeed, M. E. M., Mahmoud, N., Sugimoto, Y., Efferth, T., & Abdel-Aziz, H. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00481 · Cited by 58
“CDK-cyclin complexes tightly monitor the four sequential phases of cell cycle, namely G1, S, G2, and M phase, and dysregulation in any phase results in uncontrolled cell growth (Asghar et al., 2015).”
BackgroundMa, Q. (2019) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-018-0129-6 · Cited by 58
Saleem, H., Abdul, U. K., Küçükosmanoğlu, A., Houweling, M., Cornelissen, F. M. G., Heiland, D. H., Hegi, M. E., Kouwenhoven, M. C. M., Bailey, D. S., Würdinger, T., et al. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.04.002 · Cited by 59
Synthesis of a new series of pyrazolo[1,5-a]pyrimidines as CDK2 inhibitors and anti-leukemia
Almehmadi, S. J., Alsaedi, A. M. R., Harras, M. F., & Farghaly, T. A. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105431 · Cited by 58
Non-canonical roles of PFKFB3 in regulation of cell cycle through binding to CDK4
Jia, W., Zhao, X., Zhao, L., Yan, H., Li, J., Yang, H., Huang, G., & Liu, J. (2018) · Oncogene · doi:10.1038/s41388-017-0072-4 · Cited by 58
Al-Salem, H. S., Arifuzzaman, M., Alkahtani, H. M., Abdalla, A. N., Issa, I. S., Alqathama, A. A., Albalawi, F. S., & Rahman, A. F. M. M. (2020) · Molecules · doi:10.3390/molecules25194400 · Cited by 57
“The CDK2 Assay Kit comes in a convenient 96-well format, with enough purified recombinant CDK2/CyclinA2 enzyme, CDK substrate peptide, ATP and kinase assay buffer for 100 enzyme reactions [67].”
MethodYu, H., Yin, S., Zhou, S., Shao, Y., Sun, J., Pang, X., Han, L., Zhang, Y., Gao, X., Jin, C., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0660-4 · Cited by 56
Cyclin‐dependent kinases: Masters of the eukaryotic universe
Pluta, A. J., Studniarek, C., Murphy, S., & Norbury, C. J. (2023) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1816 · Cited by 57
Cotargeting CDK4/6 and BRD4 Promotes Senescence and Ferroptosis Sensitivity in Cancer
Zhu, X., Fu, Z., Dutchak, K., Arabzadeh, A., Milette, S., Steinberger, J., Morin, G., Monast, A., Pilon, V., Kong, T., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-1749 · Cited by 57
Structure-based discovery of cyclin-dependent protein kinase inhibitors
Martin, M. P., Endicott, J., & Noble, M. E. M. (2017) · Essays in Biochemistry · doi:10.1042/ebc20170040 · Cited by 57
Recent Advances in CDK Inhibitors for Cancer Therapy
Heptinstall, A. B., Adiyasa, I., Cano, C., & Hardcastle, I. R. (2018) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0246 · Cited by 56
Santoni, M., Occhipinti, G., Romagnoli, E., Miccini, F., Scoccia, L., Giulietti, M., Principato, G., Saladino, T., Piva, F., & Battelli, N. (2019) · BioDrugs · doi:10.1007/s40259-019-00382-1 · Cited by 56
Depletion of CDC5L inhibits bladder cancer tumorigenesis
Zhang, Z., Mao, W., Wang, L., Liu, M., Zhang, W., Wu, Y., Zhang, J., Mao, S., Geng, J., & Yao, X. (2019) · Journal of Cancer · doi:10.7150/jca.32850 · Cited by 56
“Thus, targeting the cell cycle is increasingly considered an approach to cancer therapy [21, 22].”
BackgroundCyclin-dependent kinase inhibitors in brain cancer: current state and future directions
Jurić, V., & Murphy, B. M. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2019.105 · Cited by 56
“The essential roles of CDKs in the intracellular control of the cell cycle and regulation of transcription and DNA repair([79]) make them highly suitable as targets of inhibitors for the treatment of cancer.”
BackgroundXie, D., Song, H., Wu, T., Li, D., Hua, K., Xu, H., Zhao, B., Wu, C., Hu, J., Ji, C., et al. (2018) · Oncology Reports · doi:10.3892/or.2018.6741 · Cited by 55
Cancer cell cycle dystopia: heterogeneity, plasticity, and therapy
Witkiewicz, A. K., Kumarasamy, V. M., Sanidas, I., & Knudsen, E. S. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.04.006 · Cited by 56
Self-citationOptimizing drug design by merging generative AI with a physics-based active learning framework
Filella-Mercè, I., Molina, A., Díaz, L., Orzechowski, M., Berchiche, Y. A., Zhu, Y. M., Vilalta-Mor, J., Malo, L., Yekkirala, A. S., Ray, S. S., et al. (2025) · Communications Chemistry · doi:10.1038/s42004-025-01635-7 · Cited by 56
“The fi rst target, cyclin-dependent kinase 2 (CDK2), regulates cell progression and is a potential therapeutic target for certaintumors 56,57 .”
Liu, Y., Hao, M., Leggett, A. L., Gao, Y., Ficarro, S. B., Che, J., He, Z., Olson, C. M., Marto, J. A., Kwiatkowski, N. P., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01929 · Cited by 55
Hu, R., Wang, W., Yang, Y.-Y., Hu, X.-T., Wang, Q., Zuo, W., Xu, Y., Feng, Q., & Wang, N. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113922 · Cited by 55
Yin, L., Li, H., Liu, W., Yao, Z., Cheng, Z., Zhang, H., & Zou, H. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.12.003 · Cited by 54
Ye, P., Feng, L., Shi, S., & Dong, C. (2022) · Cancers · doi:10.3390/cancers14092101 · Cited by 56
“Ideally, the combination of chemotherapeutic drugs and lncRNA target drugs can reduce the dose and side effects for BC patients.”
Rej, R. K., Allu, S. R., Roy, J., Acharyya, R. K., Kiran, I. N. C., Addepalli, Y., & Dhamodharan, V. (2024) · Pharmaceuticals · doi:10.3390/ph17040494 · Cited by 55
Molecular Genetic Analysis of Ovarian Brenner Tumors and Associated Mucinous Epithelial Neoplasms
Tafe, L. J., Muller, K. E., Ananda, G., Mitchell, T. N., Spotlow, V., Patterson, S. E., Tsongalis, G. J., & Mockus, S. M. (2016) · American Journal Of Pathology · doi:10.1016/j.ajpath.2015.11.008 · Cited by 54
PKC-alpha modulation by miR-483-3p in platinum-resistant ovarian carcinoma cells
Arrighetti, N., Cossa, G., Cecco, L. D., Stucchi, S., Carenini, N., Corna, E., Gandellini, P., Zaffaroni, N., Perego, P., & Gatti, L. (2016) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2016.08.005 · Cited by 54
Sisinni, L., Maddalena, F., Condelli, V., Pannone, G., Simeon, V., Bergolis, V. L., Lopes, E., Piscazzi, A., Matassa, D. S., Mazzoccoli, C., et al. (2017) · The Journal of Pathology · doi:10.1002/path.4936 · Cited by 54
“Deregulation of cell cycle progression is a general feature of human cancer cells due to aberrant activity of cyclin-dependent kinases (CDKs), CDK inhibitors (CDKis), and cyclins [1].”
BackgroundIt takes a team: a gain-of-function story of p53-R249S
Wang, H., Liao, P., Zeng, S. X., & Lu, H. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjy086 · Cited by 54
Cyclin-Dependent Kinase 4 and 6 Inhibitors in Cell Cycle Dysregulation for Breast Cancer Treatment
Susanti, N. M. P., & Tjahjono, D. H. (2021) · Molecules · doi:10.3390/molecules26154462 · Cited by 54
“Flavopiridol binds to CDK9’s active conformation (αCin, DFG-Din, and open activation segments) and is grouped as a type I inhibitor [72].”
BackgroundInfluentialTargeting CDK4/6 for Anticancer Therapy
Qi, J., & Ouyang, Z. (2022) · Biomedicines · doi:10.3390/biomedicines10030685 · Cited by 53
“Understanding mechanisms of resistance offer opportunities in developing combination therapy [29].”
BackgroundInfluentialLin, W., Zeng, Y., Weng, L., Yang, J., & Zhuang, W. (2024) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-024-00770-6 · Cited by 53
“Palbociclib exhibits comparable potency for both CDK4 and CDK6, whereas abemaciclib demonstrates a higher affinity for CDK4 [25, 27], resulting in relatively lower hematologic toxicity.”
BackgroundBaltus, C. B., Jorda, R., Marot, C., Berka, K., Bazgier, V., Kryštof, V., Prié, G., & Viaud‐Massuard, M. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.12.023 · Cited by 53
CDK4/6 inhibitors in HER2-positive breast cancer
Corona, S. P., Ravelli, A., Cretella, D., Cappelletti, M. R., Zanotti, L., Dester, M., Gobbi, A., Petronini, P. G., & Generali, D. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.02.022 · Cited by 53
CCRK is a novel signalling hub exploitable in cancer immunotherapy
Mok, M. T. S., Zhou, J., Tang, W., Zeng, X., Oliver, A. W., Ward, S. E., & Cheng, A. S. L. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.01.008 · Cited by 53
Gopalan, P. K., Villegas, A. G., Cao, C., Pinder-Schenck, M. C., Chiappori, A., Hou, W., Zajac‐Kaye, M., Ivey, A. M., & Kaye, F. J. (2018) · Oncotarget · doi:10.18632/oncotarget.26424 · Cited by 53
“To date, more than 200 clinical trials with CDK4/6 inhibitors have been completed or are underway in many different disease types, including breast cancer, mantle cell lymphoma, liposarcoma, NSCLC, glioblastoma multiforme, germ cell tumors, melanoma and SCLC [8, 17, 19, 20].”
BackgroundRaschi, E., & De Ponti, F. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01235 · Cited by 48
“CDKs were expected to be key therapeutic targets in cancer and pan-CDK inhibitors were initially designed, albeit with disappointing results (Asghar et al., 2015).”
BackgroundLDHA as a regulator of T cell fate and its mechanisms in disease
Dai, M., Wang, L., Yang, J., Chen, J., Dou, X., Chen, R., Ge, Y., & Lin, Y. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114164 · Cited by 52
MDM2-p53 in liposarcoma: The need for targeted therapies with novel mechanisms of action
Somaiah, N., & Tap, W. D. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102668 · Cited by 53
Zhang, W., Lei, C., Fan, J., & Wang, J. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.06.034 · Cited by 52
Kinase-independent function of E-type cyclins in liver cancer
Geng, Y., Michowski, W., Chick, J. M., Wang, Y. E., Jecrois, M., Sweeney, K. E., Liu, L., Han, R. C., Ke, N., Zagożdżon, A., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1711477115 · Cited by 52
Flavopiridol as cyclin dependent kinase (CDK) inhibitor: a review
Deep, A., Marwaha, R. K., Marwaha, M. G., Jyoti, J., Nandal, R., & Sharma, A. K. (2018) · New Journal of Chemistry · doi:10.1039/c8nj04306j · Cited by 52
Targeting CDK7 increases the stability of Snail to promote the dissemination of colorectal cancer
Zhou, Y., Lu, L., Jiang, G., Chen, Z., Li, J., An, P., Chen, L., Du, J., & Wang, H. (2018) · Cell Death and Differentiation · doi:10.1038/s41418-018-0222-4 · Cited by 52
Cheng, C., Yun, F., Ullah, S., & Yuan, Q. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112073 · Cited by 52
Therapeutic Targeting of the General RNA Polymerase II Transcription Machinery
Martin, R., Hébert, T. E., & Tanny, J. C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093354 · Cited by 52
“Clinical trials have thus far failed to show any efficacy for roscovitine as a monotherapy for cancer [55,81].”
BackgroundKumarasamy, V. M., Wang, J., Roti, M., Wan, Y., Dommer, A. P., Rosenheck, H. R., Putta, S., Trub, A. G., Bisi, J., Strum, J. C., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56674-4 · Cited by 53
“However, thestructuralsimilarity in the catalytic domains of CDK2 and CDK1 has posed challenges for drug development 25 .”
Self-citationMicroRNA-802 suppresses breast cancer proliferation through downregulation of FoxM1
Yuan, F., & Wang, W. T. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.3921 · Cited by 51
Seftel, M. D., Kuruvilla, J. G., Kouroukis, T., Banerji, V., Fraser, G. A. M., Crump, M., Kumar, R., Chalchal, H. I., Salim, M., Laister, R. C., et al. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1239259 · Cited by 51
“[3,4] Cyclin-dependent kinases (CDKs) are enzymes that function as critical regulators of the cell cycle and in the production of mRNA.[5] AT7519M is a potent nanomolar inhibitor of CDKs 1, 2, 4, 5, 9 and acts both via G1/G2 cell cycle arrest (CDK1 and 2) as well as mRNA transcriptional inhibition (CDK9).”
BackgroundZhen, Z., Ren, S.-H., Ji, H., Ma, J., Ding, X., Feng, F., Chen, S.-L., Zou, P., Ren, J., & Jia, L. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.08.023 · Cited by 51
Antonello, Z. A., Hsu, N. Y.-H., Bhasin, M., Roti, G., Joshi, M., Hummelen, P. V., Ye, E., Lo, A. S., Karumanchi, S. A., Bryke, C. R., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.21262 · Cited by 51
“Aberrant regulation of the cell cycle is one of the crucial mechanisms in tumor progression [45], which includes deregulation of checkpoints from G1 phase until mitosis [44].”
BackgroundLuo, Q., Wu, X., Chang, W., Zhao, P., Nan, Y., Zhu, X., Katz, J. P., Su, D., & Liu, Z. (2019) · Cell Death and Differentiation · doi:10.1038/s41418-019-0475-6 · Cited by 51
Mechanisms of endocrine resistance in hormone receptor-positive breast cancer
Gao, Y., Yu, Y., Zhang, M., Yu, W., & Kang, L. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1448687 · Cited by 50
Cocco, E., Lopez, S., Black, J., Bellone, S., Bonazzoli, E., Predolini, F., Ferrari, F., Schwab, C. L., Menderes, G., Zammataro, L. A., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.198 · Cited by 50
“The use of CDK2 inhibitors to indirectly interfere with CCNE1 function has been therefore proposed as an alternative approach in the past years (Asghar et al, 2015; Taylor-Harding et al, 2015; Yang et al, 2015).”
BackgroundA cyclin-dependent kinase inhibitor, dinaciclib in preclinical treatment models of thyroid cancer
Lin, S., Lin, J., Hsueh, C., Chou, T., & Wong, R. J. (2017) · PLoS ONE · doi:10.1371/journal.pone.0172315 · Cited by 50
Reassessing the Potential of Myb-targeted Anti-cancer Therapy
Liu, X., Xu, Y., Han, L., & Yi, Y. (2018) · Journal of Cancer · doi:10.7150/jca.23992 · Cited by 50
“However, clinical trials of Flavopiridol in solid tumors were discontinued because of adverse events and low efficacy [64].”
Background
Metadata
- Authors
- Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S.
- Affiliations
- Institute of Cancer Research (GB)
- Harold C. Simmons Comprehensive Cancer Center (US)
- Royal Marsden NHS Foundation Trust (GB)
- Corresponding author
- Knudsen, Erik S.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2015-01-30
- Volume
- 14
- Issue
- 2
- Pages
- 130-146
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- PMC
- PMC4480421
- OpenAlex
- W2057272791
- Cited by
- 1,767
- References
- 210
- Citations by year
- 2026: 100 · 2025: 157 · 2024: 157 · 2023: 170 · 2022: 180 · 2021: 200 · 2020: 185 · 2019: 148 · 2018: 150 · 2017: 161 · 2016: 112 · 2015: 46
- FWCI
- 27.85
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Bristol-Myers Squibb
- F. Hoffmann-La Roche
- Consortium canadien en neurodégénérescence associée au vieillissement
- Cancer Research UK (16642)
- National Cancer Institute (R01CA129134, CA129134, CA188650, R01CA188650, CA163863, R01CA163863)
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- cyclin-dependent kinases, cyclin-dependent kinase inhibitors, CDK4, CDK6, CDK2, CDK1, cell cycle regulation, G1 phase, chromosome stability, S phase, anticancer drug development, clinical trials, patient stratification, kinase selectivity
- MeSH terms
- Animals, Antineoplastic Agents, Cell Cycle, Clinical Trials as Topic, Drug Evaluation, Preclinical, Humans, Neoplasms, Molecular Structure, Signal Transduction, Gene Expression Regulation, Neoplastic, Cyclin-Dependent Kinases, Drug Discovery, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.